About: Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $58.98 (-0.96%)
XENENASDAQXenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc share price
XENE price activity
Last Price
$58.980
Change (24hr)
-0.57 USD (-0.96%)
Volume
489.33K
Volume (4w avg)
-
Open
$59.04
Day Range
$58.53 - $59.81
Previous Close
$59.55
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
XENE price performance
Delayed
09 Sep, 8:00 pm GMT+0
XENE Market Signals